EMAIL THIS PAGE TO A FRIEND

Neurobiology of disease

Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.


PMID 25174890

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant Parkinson's disease (PD). The clinical and neurochemical features of LRRK2-linked PD are similar to idiopathic disease although neuropathology is somewhat heterogeneous. Dominant mutations in LRRK2 precipitate neurodegeneration through a toxic gain-of-function mechanism which can be modeled in transgenic mice overexpressing human LRRK2 variants. A number of LRRK2 transgenic mouse models have been developed that display abnormalities in dopaminergic neurotransmission and alterations in tau metabolism yet without consistently inducing dopaminergic neurodegeneration. To directly explore the impact of mutant LRRK2 on the nigrostriatal dopaminergic pathway, we developed conditional transgenic mice that selectively express human R1441C LRRK2 in dopaminergic neurons from the endogenous murine ROSA26 promoter. The expression of R1441C LRRK2 does not induce the degeneration of substantia nigra dopaminergic neurons or striatal dopamine deficits in mice up to 2years of age, and fails to precipitate abnormal protein inclusions containing alpha-synuclein, tau, ubiquitin or autophagy markers (LC3 and p62). Furthermore, mice expressing R1441C LRRK2 exhibit normal motor activity and olfactory function with increasing age. Intriguingly, the expression of R1441C LRRK2 induces age-dependent abnormalities of the nuclear envelope in nigral dopaminergic neurons including reduced nuclear circularity and increased invaginations of the nuclear envelope. In addition, R1441C LRRK2 mice display increased neurite complexity of cultured midbrain dopaminergic neurons. Collectively, these novel R1441C LRRK2 conditional transgenic mice reveal altered dopaminergic neuronal morphology with advancing age, and provide a useful tool for exploring the pathogenic mechanisms underlying the R1441C LRRK2 mutation in PD.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1302886
ANTI-ATP11C (CENTER) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
HPA030830
Anti-ATP11C antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2106681
Anti-ATP11C antibody produced in rabbit, affinity isolated antibody
SAB4300647
Anti-GFAP antibody produced in rabbit, affinity isolated antibody
HPA056030
Anti-GFAP antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2107063
Anti-GFAP antibody produced in rabbit, affinity isolated antibody
SAB2101352
Anti-LMNB1 antibody produced in rabbit, affinity isolated antibody
SAB1410759
Anti-LMNB1 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
HPA014293
Anti-LRRK2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
AV43845
Anti-SLC18A2 antibody produced in rabbit, affinity isolated antibody, lyophilized powder
V9014 Anti-VMAT2 antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
SAB1305528 MONOCLONAL ANTI-PARK8 (LRRK2) antibody produced in mouse, clone 133AT720, IgG fraction of antiserum, buffered aqueous solution
SAB1305527 MONOCLONAL ANTI-PARK8 (LRRK2) antibody produced in mouse, clone 133AT1218, IgG fraction of antiserum, buffered aqueous solution